PMDA drug package insert
マキサカルシトール静注透析用2.5μg「ニプロ」
PMDA Prescription drug · シオノギファーマ株式会社 · package insert Oct 1, 2023
Key facts
| Brand names | マキサカルシトール静注透析用2.5μg「ニプロ」, マキサカルシトール静注透析用5μg「ニプロ」, マキサカルシトール静注透析用10μg「ニプロ」 |
|---|---|
| Nonproprietary names | マキサカルシトール |
| Companies | 製造販売元／シオノギファーマ株式会社, 販売／ニプロ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 二次性副甲状腺機能亢進症治療剤 |
| Therapeutic category codes | 873112 |
| YJ codes | 3112401A1050, 3112401A2057, 3112401A3053 |
| Approval numbers | 22700AMX00872000, 22700AMX00873000, 22700AMX00874000 |
| Package insert edition | 第1版 |
| Package insert date | Oct 1, 2023 |
| PMDA document key | 343018_3112401A1050_2 |
| PMDA company code | 343018 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: